Balyasny Asset Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Balyasny Asset Management’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-38,172	Closed	-$141K	–	1621
2016 Q1	$141K	Buy	+38,172	New	+$236K	﹤0.01%	1170
2015 Q3	–	Sell	-205,210	Closed	-$3.89M	–	1556
2015 Q2	$3.89M	Sell	205,210 -454,659	-69%	-$9.84M	0.02%	647
2015 Q1	$17.3M	Buy	+659,869	New	+$16.8M	0.14%	224
2013 Q3	–	Sell	-70,000	Closed	-$4.43M	–	786
2013 Q2	$4.43M	Buy	+70,000	New	+$3.72M	0.07%	314

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Balyasny Asset Management's AEGR Position: Q2 2016 in Review

Balyasny Asset Management sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 38,172 shares — an estimated $141K sold.

Balyasny Asset Management first reported a position in AEGR in Q2 2013 and held it in 4 quarters. The position peaked at $17.3M in Q1 2015. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

Balyasny Asset Management reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Balyasny Asset Management sold 38,172 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $141K.
Balyasny Asset Management first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
Balyasny Asset Management's Aegerion Pharmaceuticals position peaked at $17.3M in Q1 2015.
71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Balyasny Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.